A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

PHASE2RecruitingINTERVENTIONAL
Enrollment

770

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

May 15, 2026

Study Completion Date

May 15, 2026

Conditions
Influenza, Human
Interventions
BIOLOGICAL

Flu mRNA (Formulation A)

One dose of Flu mRNA (Formulation A) received intramuscularly.

BIOLOGICAL

Flu mRNA (Formulation B)

One dose of Flu mRNA (Formulation B) received intramuscularly.

COMBINATION_PRODUCT

Comparator 1

One dose of Comparator 1 received intramuscularly.

COMBINATION_PRODUCT

Comparator 2

One dose of Comparator 2 received intramuscularly.

COMBINATION_PRODUCT

Comparator 3

One dose of Comparator 3 received intramuscularly.

Trial Locations (22)

14609

RECRUITING

GSK Investigational Site, Rochester

23606

RECRUITING

GSK Investigational Site, Newport News

27408

RECRUITING

GSK Investigational Site, Greensboro

29405

RECRUITING

GSK Investigational Site, North Charleston

30281

RECRUITING

GSK Investigational Site, Atlanta

33012

RECRUITING

GSK Investigational Site, Hialeah

33186

RECRUITING

GSK Investigational Site, Miami

33458

RECRUITING

GSK Investigational Site, Jupiter

36207

RECRUITING

GSK Investigational Site, Anniston

44122

RECRUITING

GSK Investigational Site, Cleveland

46383

RECRUITING

GSK Investigational Site, Valparaiso

66219

RECRUITING

GSK Investigational Site, Lenexa

75115

RECRUITING

GSK Investigational Site, DeSoto

76135

RECRUITING

GSK Investigational Site, Fort Worth

78705

RECRUITING

GSK Investigational Site, Austin

89706

RECRUITING

GSK Investigational Site, Carson City

92120

RECRUITING

GSK Investigational Site, San Diego

92123

RECRUITING

GSK Investigational Site, San Diego

94598

RECRUITING

GSK Investigational Site, Walnut Creek

95628

RECRUITING

GSK Investigational Site, Fair Oaks

98104

RECRUITING

GSK Investigational Site, Seattle

01103

RECRUITING

GSK Investigational Site, Springfield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT07121192 - A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older | Biotech Hunter | Biotech Hunter